Deutsche Bank Upgrades Novo Nordisk (NVO) to Buy
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Deutsche Bank upgraded Novo Nordisk (NYSE: NVO) from Hold to Buy with a price target of DKK 360. Analyst Tim Race anticipates long-term growth.
"We upgrade Novo Nordisk to Buy from Hold, reflecting the company's positive long-term prospects in diabetes," said Race.
The analyst added, "We believe that US price fears in the insulin subsegment are well known and reflected by the company's 24% share price decline YTD (-9% vs SXDP). This leaves the shares trading on 18x 2017E PE, a 15% premium to but a 10 year low versus peers. At these levels we now see upside as the insulin market is not permanently broken and we expect significant growth from GLP-1's."
Shares of Novo Nordisk closed at $44.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: MKM Partners Upgrades Masco (MAS) to Buy
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Oppenheimer Raises Price Target on Capital One Financial (COF) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Upgrades
Related EntitiesDeutsche Bank
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!